On the other hand, patients with EGFR-TKI sensitive NSCLC might rather benefit from combinatorial treatment with anti-CTLA-4 antibody, since anti-PD-L1 antibodies can only be efficient in tumor cells with high PD-L1 expression [103]. Here, EGFR is linked to non-small cell lung carcinoma.